Regulation of the sodium/iodide symporter by retinoids - a review

Summary:

Decrease or loss of iodide uptake, due to impaired expression and/or function of the sodium/iodide-symporter (NIS), is a major obstacle to the treatment of advanced thyroid carcinomas by radioiodide therapy. Several approaches are being evaluated to optimise or restore sufficient iodide transport in those cases, among them retinoid therapy. Retinoids with their growth-inhibiting and differentiation-inducing properties have been repeatedly used for treatment and chemoprevention of various cancers. In thyroid carcinoma cell lines they trigger changes in gene expression that may be interpreted as partial redifferentiation. Especially, they stimulate NIS mRNA expression and iodide uptake in human follicular thyroid carcinoma cells. Moreover, they also increase NIS expression and function in human mammary tumour cells. In a clinical pilot study to evaluate the feasibility of retinoid redifferentiation in the case of otherwise untreatable thyroid cancers, 21 of 50 patients showed an increase of radioiodide uptake after 5 weeks. This indicates that increasing NIS activity and radioiodide uptake by retinoic acid redifferentiation may be a therapeutic alternative for thyroid cancers refractory to other therapeutic modalities and probably also for mammary cancer.

Key words:

Thyroid cancer - breast cancer - redifferentiation - radioiodide therapy - pilot study

References

• 1 Boland A, Ricard M, Opolon P, Bidart J M, Yeh P, Filetti S, Schlumberger M, Perricaudet M. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.  Cancer Res 2000 Jul 1. 60(13) 3484-3492 2000; 
• 2 Chambon P. A decade of molecular biology of retinoic acid.  FASEB J. 10 940-954 1996; 
• 3 Cho J Y, Xing S, Liu X, Buckwalter T L, Hwa L, Sferra T J, Chiu I M, Jhiang S M. Expression and activity of human Na⁺/I^- symporter in human glioma cells by adenovirus-mediated gene delivery.  Gene Ther 2000 May. 7(9) 740-749 2000; 
• 4 Filetti S, Bidart J M, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell.  Eur J Endocrinol. 141 443-457 1999; 
• 5 Garcin H, Higueret P, Amoikon K. Effects of a large dose of retinol or retinoic acid on the thyroid hormones in the rat.  Ann Nutr Metab. 28 92-100 1984; 
• 6 Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack H J. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.  J Nucl Med. 39 1903-1906 1998a; 
• 7 Grünwald F, Pakos E, Bender H, Menzel C, Otte R, Palmedo H, Pfeifer U. Redifferentiation therapy with retinoic acid in follicular thyroid cancer.  J Nucl Med. 39 1555-1558 1998b; 
• 8 Hong W K, Itri L M. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, (eds). THE RETINOIDS: Biology, chemistry and medicine, Second Edition. pp. 597-630 Raven Press Ltd., New York 1994
• 9 Körber C, Schmutzler C, Rendl J, Köhrle J, Griesser H, Simon D, Reiners C. Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid.  Clin Nucl Med. 24 849-851 1999; 
• 10 Kogai T, Schultz J J, Johnson L S, Huang M, Brent G A. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line.  Proc Natl Acad Sci USA. 97 8519-8524 2000; 
• 11 Koong S-S, Reynolds J C, Movius E G, Keenan A M, Ain K B, Lakshman M C, Robbins J. Lithium as a potential adjuvant to ¹³¹I therapy of metastatic, well differentiated thyroid carcinoma.  J Clin Endocrinol Metab. 84 912-916 1999; 
• 12 Mandell R B, Mandell L Z, Link C J. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.  Cancer Res. 59 661-668 1999; 
• 13 Mazzaferri E L. An overview of the management of papillary and follicular thyroid carcinoma.  Thyroid. 9 421-427 1999; 
• 14 Schiller U, Hoffmann W, Bamberg M, Rodemann H P. All-trans retinoic acid modulates the radiosensitivity of proliferating cells.  Int J Cancer. 70 488-490 1997; 
• 15 Schlumberger M J. Papillary and follicular thyroid carcinoma.  N Engl J Med. 338 297-306 1998; 
• 16 Schmutzler C, Winzer R, Meissner-Weigl J, Köhrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells.  Biochem Biophys Res Commun. 240 832-838 1997; 
• 17 Schmutzler C, Köhrle J. Implications of th molecular characterization of the sodium-iodide symporter (NIS).  Exp Clin Endocrinol Diabetes 106 ((Suppl 3)) S1-S10 1998; 
• 18 Schmutzler C, Brtko J, Winzer R, Jakobs T C, Meissner-Weigl J, Simon D, Goretzki P E, Kohrle J. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues.  Int J Cancer. 76 368-376 1998; 
• 19 Schmutzler C, Köhrle J. Retinoic acid redifferentiation therapy for thyroid cancer.  Thyroid. 10 393-406 2000; 
• 20 Schmutzler C, Schmitt T L, Glaser F, Köhrle J, Loos U. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. 11th International Congress of Endocrinology, Sydney, Australia 29th October-2nd November 2000 (Abstract)
• 21 Sherman S I, Gopal J, Haugen B R, Chiu A C, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands.  N Engl J Med. 340 1075-1079 1999; 
• 22 Shimura H, Haraguchi K, Miyazaki A, Endo T, Onaya T. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na⁺/I^- symporter gene.  Endocrinology. 138 4493-4496 1997; 
• 23 Simkins S. Use of massive doses of vitamin A in the treatment of hyperthyroidism.  J Clin Endocrinol Metab. 7 574 1947; 
• 24 Simon D, Köhrle J, Schmutzler C, Mainz K, Reiners C, Röher H D. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results.  Exp Clin Endocrinol Metab 104 ((Suppl 4)) 13-15 1996; 
• 25 Simon D, Köhrle J, Reiners C, Boerner A R, Schmutzler C, Mainz K, Goretzki P E, Röher H D. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma.  World J Surg. 22 569-574 1998a; 
• 26 Simon D, Köhrle J, Reiners C, Groth P, Börner A R, Grünwald F, Riccabona G, Mainz K. Redifferentiation therapy in thyroid cancer - results of a multicenter pilot study.  Thyroid. 8 1217 1998b (Abstract); 
• 27 Spitzweg C, Zhang S, Bergert E R, Castro M R, McIver B, Heufelder A E, Tindall D J, Young C Y, Morris J C. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer lines.  Cancer Res. 59 2136-2141 1999; 
• 28 Tazebay U H, Wapnir I L, Levy O, Dohan O, Zuckier L S, Zhao Q H, Deng H F, Amenta P S, Fineberg S, Pestell R G, Carrasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer.  Nat Med. 6 871-878 2000; 
• 29 van Herle A J, Agatep M L, Padua III D N, Totanes T L, Canlapan D V, van Herle H ML, Juillard G JF. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro.  J Clin Endocrinol Metab. 71 755-763 1990; 
• 30 Venkataraman G M, Yatin M, Marcinek R, Ain K B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na⁺/I^- symporter gene methylation status.  J Clin Endocrinol Metab. 84 2449-2457 1999;